Japanese Oral Antidiabetics Market to Reach Sales Worth US$ 2.9 Billion by 2016
A new report from IMARC Group expects new drug launches to drive the growth of the Japanese Oral Antidiabetics market during 2011-2016.
- (1888PressRelease) October 01, 2011 - In its new report entitled "Japan Diabetes Market Report & Forecast 2011-2016", IMARC Group, one of the world's leading providers of life science market intelligence expects the Japanese oral Antidiabetics market to reach revenues worth US$ 2.9 Billion by 2016. The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in Japan. The report has segmented the Japanese diabetes market into two segments - Insulin and the Oral Antidiabetics market. For each of the aforementioned categories, the report provides historical and future market sales of key classes, key companies, key drugs and key molecules.
The research study serves as an exceptional tool to understand the market trends, therapeutic structure, competitive structure and the outlook of the Japanese diabetes market till 2016. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Japanese diabetes market in some form or the other.
Key Questions Answered in this Report:
• What is the size and demographical breakup of the diabetes population in Japan?
• What are the current and future diagnosis and drug treatment rates of diabetes in Japan?
• How has the diabetes market behaved since 2005 and what are the expected trends till 2016?
• What has been the historical performance of the Japanese Insulin market during 2005-2010 and its outlook till 2016?
• What has been the performance of top classes, top players, top molecules and top drugs in the Insulin market during 2005-2010?
• What has been the historical performance of the Oral Antidiabetics market during 2005-2010 and its outlook till 2016?
• What has been the performance of top classes, top players, top molecules and top drugs in the Oral Antidiabetics market during 2005-2010?
Why should you buy this report?
• Gain a deeper understanding about the prevalence, diagnosis and treatment of diabetes in Japan and identify your potential patient pool.
• Analyze the historical, current and future trends in the Insulin and Oral Antidiabetics market to identify potential classes, drugs, partners and competitors for market entry and expansion plans.
• Develop Investment strategies by identifying companies that have been the biggest winners and losers in the Japanese Insulin and Oral Antidiabetics market.
• Gain an insight into future market events such as patent expiry's and new product launches.
Classes Covered:
Fast acting Insulins, Long acting Insulins, Intermediate and Fast acting Insulins, Intermediate acting Insulins, Biguanides, Glitazone and Biguanide combinations, Glinides, Sulphonylureas, Glitazones, DPP-IV Inhibitors, Glinide and Biguanide Combinations, Glp-1 Agonists, Alpha-Glucosidase Inhibitors, SGLT Inhibitors and all other Oral Antidiabetic classes.
Information Sources:
Information has been sourced from both primary and secondary sources:
• Primary sources include industry surveys and face to face/telephone interviews with physicians and industry experts.
• Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, Industry Portals, government sources and access to more than 4000 paid databases.
Forecasting Methodology:
IMARC generates its product and market forecasts utilizing its extensive database of macroeconomic and sector specific data. The initial baseline forecast is generated with the most recent market data. After an initial baseline forecast, all future macroeconomic and sector specific events and assumptions are taken into account to generate the final forecast.
Table of Contents
1 Research Methodology & Market Definitions
2 Executive Summary
3 Epidemiology
3.1 Total Diabetes Patients
3.2 Patients by Gender
3.3 Patients by Age Group
3.4 Diagnosed and Drug Treated Population
4 Market Dynamics
4.1 Diabetes Market
4.1.1 Current Trends (2005-2010)
4.1.2 Forecast (2011-2016)
4.2 Insulin Market
4.2.1 Current Trends (2005-2010)
4.2.1.1 Market by Class
4.2.1.2 Market by Molecule
4.2.1.3 Top Players
4.2.1.4 Top Drugs
4.2.2 Forecast (2011-2016)
4.3 Oral Antidiabetics
4.3.1 Current Trends (2005-2010)
4.3.1.1 Market by Class
4.3.1.2 Top Players
4.3.1.3 Top Drugs
4.3.2 Forecast (2011-2016)
To buy the complete report or to get a free sample:
Call: +91-120-425-6531 (Asia), +44-844-774-3860 (Europe), +1-631-791-1145 (America)
Email: sales ( @ ) imarcgroup dot com
For more information please visit: www.imarcgroup.com
###
space
space
Contact Information
- Krishna Sharma
- Imarc Group
- 21/601 Eastend Apartment Mayur Vihar Phase-1 Extention Delhi-110096, India
- 110096
- Voice: 91-11-43095788
- Visit our Site
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam